Bioventus (BVS)
(Delayed Data from NSDQ)
$4.07 USD
-0.08 (-1.93%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.07 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BVS 4.07 -0.08(-1.93%)
Will BVS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BVS
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?
BVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Value Medical Stocks to Buy for Safety Amid Market Volatility
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
Other News for BVS
Notable Two Hundred Day Moving Average Cross - BVS
Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Bioventus price target raised by $3 at Craig-Hallum, here's why
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)